Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Page Path

HOME
ARTICLE CATEGORY
Editorial

Editorial

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0055

View: 2432 Download: 48

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease

Byeong Geun Song, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):411-413. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0058

View: 632 Download: 24

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 639 Download: 39

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 765 Download: 32

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 682 Download: 29

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 754 Download: 68

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 707 Download: 39

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 647 Download: 22

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 802 Download: 45

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 686 Download: 35

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 662 Download: 40

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 625 Download: 30

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 725 Download: 43

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054

View: 631 Download: 35

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 659 Download: 43

The current trends in the health burden of primary liver cancer across the globe

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(2):358-362. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0092

View: 757 Download: 30

The latest global burden of liver cancer: A past and present threat

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):355-357. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0070

View: 667 Download: 27

Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan

San-Chi Chen

Clin Mol Hepatol. 2023;29(2):352-354. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0101

View: 718 Download: 34

Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap

Shen-Yung Wang

Clin Mol Hepatol. 2023;29(2):349-351. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0082

View: 746 Download: 28

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0094

View: 681 Download: 29

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences

Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen

Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0106

View: 744 Download: 32

The clinical management of hepatocellular carcinoma in China: Progress and challenges

Shan Shan, Jidong Jia

Clin Mol Hepatol. 2023;29(2):339-341. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0077

View: 738 Download: 37

Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma

Do Young Kim

Clin Mol Hepatol. 2023;29(2):335-338. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0107

View: 693 Download: 28

What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

Min Kyung Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(2):332-334. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0080

View: 655 Download: 21

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

View: 1390 Download: 112 Citation: 1

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0333

View: 1521 Download: 72 Citations: 2

Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey

Susana G Rodrigues

Clin Mol Hepatol. 2023;29(1):110-112. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0414

View: 1535 Download: 64

Non-invasive tests-based risk stratification: Baveno VII and beyond

Georg Semmler, Mathias Jachs, Mattias Mandorfer

Clin Mol Hepatol. 2023;29(1):105-109. Published online November 23, 2022

DOI: https://doi.org/10.3350/cmh.2022.0361

View: 1667 Download: 70 Citations: 2

The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(1):102-104. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0353

View: 1410 Download: 96 Citation: 1

The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(1):99-101. Published online October 27, 2022

DOI: https://doi.org/10.3350/cmh.2022.0321

View: 1515 Download: 59

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

First decision

09 Days

Publication after acceptance

07 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 4109	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 2677	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2432	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Viewed By 2405	Recent updates on the management of autoimmune hepatitis
Viewed By 2401	Management of refractory ascites

MOST CITED (2021-2023)

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 285

TOTAL : 1298972